Werewolf Therapeutics, Inc.

Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has leveraged its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics’ most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.

Current securities

1. S-4 filingSep 22, 2026
2. 425 filingAug 21, 2026
3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureAug 21, 2026
4. Entry into a Material Definitive AgreementAug 20, 2026
5. 10-Q filingJul 31, 2026